SSG
FDMT icon

Summit Securities Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Summit Securities Group’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-977
Closed -$3.63K – 1125
2025
Q2 		$3.63K Buy
+977
New +$3.43K ﹤0.01% 1003
2024
Q2 		– Sell
-142
Closed -$5K – 639
2024
Q1 		$5K Buy
+142
New +$3.62K ﹤0.01% 374

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Summit Securities Group's FDMT Position: Q3 2025 in Review

Summit Securities Group sold out of 4D Molecular Therapeutics (FDMT) in Q3 2025, closing a stake of 977 shares — an estimated $3.63K sold.

Summit Securities Group first reported a position in FDMT in Q1 2024 and held it in 2 quarters. The position peaked at $5K in Q1 2024. 134 funds tracked by Wall St. Rank hold FDMT as of Q3 2025.

  • Summit Securities Group reported no remaining 4D Molecular Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Summit Securities Group sold 977 4D Molecular Therapeutics shares in Q3 2025, an estimated $3.63K.
  • Summit Securities Group first reported a position in 4D Molecular Therapeutics in Q1 2024 and held it in 2 quarters.
  • Summit Securities Group's 4D Molecular Therapeutics position peaked at $5K in Q1 2024.
  • 134 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2025.

Based on Summit Securities Group's 13F filing for Q3 2025, filed 13 Nov 2025.